Aarti Pharmalabs Q1 revenue falls despite EBITDA growth

Aarti Pharmalabs reported standalone revenue of INR 375 crores for Q1 FY26, down from INR 394 crores year-on-year, with a plant shutdown affecting sales by INR 15-20 crores. However, standalone EBITDA increased 14% to INR 95 crores and profit after tax rose 9% to INR 51 crores.

The company is expanding its Xanthine derivatives capacity from 5000 MT to 9000 MT annually, targeting H2 FY26 commissioning. Its greenfield project at Atali, Gujarat is nearing completion with commercial production expected by end of Q2 FY26.